What factors drove the changes in Diamedica's revenue and profit?

What is the market's earnings forecast for Diamedica next quarter?

What were the key takeaways from Diamedica’s earnings call?

What guidance did Diamedica's management provide for the next earnings period?

What is Diamedica's latest dividend and current dividend yield?

What were the key takeaways from Diamedica's earnings call?

What does Diamedica do and what are its main business segments?

What is Diamedica's gross profit margin?

- **Preeclampsia progress**: DM199 shows dose-dependent BP drops (systolic/diastolic) and placental perfusion improvements, positioning for U.S. trial.
- **Stroke challenges**: Enrollment halved due to AI referrals; 35+ sites activated, seeking global expansion.
- **Financial stability**: $55.3M cash, net loss up 37% YoY driven by clinical costs.
- **Key milestones**: Cohort 10 expansion, FDA pre-IND update, and ReMEDy2 interim analysis in H2 2026.


**【CEO Summary Section】**
- Presented progress in preeclampsia and stroke programs, highlighting DM199's mechanism via bradykinin pathway activation.
- Preeclampsia interim results: Dose-dependent blood pressure reductions (systolic/diastolic) and uterine artery pulsatility index improvement, supporting placental perfusion claims.
- Stroke program updates: Enrollment challenges due to AI-driven referral shifts, revised U.S. trial plans for early onset preeclampsia, and $55.3M cash as of Q3 2025.
- Q&A emphasized KOL engagement, FDA pre-IND meeting progress, and Cohort 10's 12-patient expansion for U.S. trial preparation.

**【CFO Financial Commentary】**
- Cash position: $55.3M (vs. $30M prior quarter), sufficient for operations into 2027.
- R&D expenses: $6.4M/Q3, up 28% YoY, driven by ReMEDy2 expansion and preeclampsia trial costs.
- G&A: $2.6M/Q3, +37% YoY due to team expansion and IR/patent costs.
- Net loss: $8.6M/Q3, +37% YoY from clinical and manufacturing expenses.

**【Q&A Key Highlights】**
- Preeclampsia: KOLs praise placental barrier safety and blood pressure consistency; Cohort 10 IV-only dosing for U.S. trial.
- Stroke: Enrollment rates halved due to tele-neurology; 35+ sites activated, seeking OUS approvals.
- Interim analysis: Modified Rankin Scale targeting 15% improvement in non-thrombectomy patients.


DiaMedica Therapeutics Inc. (DMAC) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

DMAC

DMAC fundamentals

You can ask Aime